RenovoRx Nears Phase III Enrollment Finish for Pancreatic Cancer System, With 2027 Results Due
Updated
Updated · Fox News · May 14
RenovoRx Nears Phase III Enrollment Finish for Pancreatic Cancer System, With 2027 Results Due
1 articles · Updated · Fox News · May 14
Mid-2026 enrollment completion is now in sight for RenovoRx’s Phase III TIGeR-PaC trial, which is testing intra-arterial gemcitabine delivered through its RenovoCath system in locally advanced pancreatic cancer.
Less than 10% of standard IV chemotherapy typically reaches pancreatic tumor cells, according to trial investigators, because sparse blood vessels and dense tumor tissue block drug delivery.
Interim trial data showed a 6-month trend toward better overall survival, 8.1 months of progression-free survival improvement and 65% fewer adverse events in the TAMP arm.
The catheter-based system delivers chemotherapy into an artery near the tumor between two balloons, aiming to concentrate treatment locally in an outpatient procedure without general anesthesia.
If final Phase III data are positive in 2027, RenovoRx says they could support an FDA application and potentially extend the platform to other hard-to-treat solid tumors.
As this targeted therapy nears approval, can it compete with emerging mRNA vaccines and immunotherapies for pancreatic cancer?
This therapy offers a better quality of life, but will its cost and complexity limit access for most cancer patients?
By physically forcing chemo into tumors, has a new device finally outsmarted one of cancer's most formidable defenses?
RenovoRx’s TIGeR-PaC Phase III Trial Surpasses 100 Patients: TAMP™ Platform Advances Targeted Pancreatic Cancer Therapy
Overview
As of May 2026, the RenovoRx Phase III TIGeR-PaC trial is nearing completion, having surpassed 100 randomized patients and moving closer to its target of 114 randomizations and 86 events. This steady progress in patient enrollment and event accrual has generally led to positive market reactions, reflecting the trial’s importance. The study has already completed two pre-planned interim analyses, triggered at the 26th and 52nd events, both confirming the trial should continue. These milestones highlight the trial’s strong momentum and the anticipation surrounding its final results for patients and stakeholders.